CL
Publicaties op Oncologisch.com
PROs vs clinician-reported adverse events in a large clinical trial: findings from the phase 3 POLARIX study.
Magrolimab plus azacitidine vs physician's choice for untreated TP53-mutated acute myeloid leukemia: the ENHANCE-2 st...
Pola-R-CHP bij onbehandeld DLBCL: Aziatische POLARIX subanalyse
Polatuzumab vedotin bij onbehandeld DLBCL: POLARIX fase III